Registration Statement · S-1/A
Akari Therapeutics Plc
Registration Statement
Company context
We are an oncology company developing next-generation antibody-drug conjugates, or ADCs, designed around novel proprietary cancer-killing toxins, or payloads. We believe these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development.
Current securities
As-filed source
As filedOpen full document ↗